Global Scleroderma Therapeutics Market Report and Forecast 2023-2031

Global Scleroderma Therapeutics Market Report and Forecast 2023-2031


Global Scleroderma Therapeutics Market Outlook


The value of the global scleroderma therapeutics market was USD 1.92 billion in 2022, driven by increasing prevalence of scleroderma, rising awareness about the disease across the globe. The market is expected to grow at a CAGR of 6.20% during the forecast period of 2023-2031 to reach value of USD 3.29 billion by 2031.

Scleroderma Therapeutics: Introduction

Scleroderma, also known as systemic sclerosis, is a rare autoimmune disease that affects the skin and internal organs. The disease is characterized by excessive production and deposition of collagen in various tissues, leading to thickening, hardening, and scarring. Scleroderma can affect different parts of the body, including the skin, lungs, kidneys, heart, and digestive system. The disease is chronic and progressive, and there is currently no cure. However, several treatments are available to manage symptoms and slow down the progression of the disease.

The global scleroderma therapeutics market is driven by the increasing prevalence of scleroderma, rising awareness about the disease, and the availability of a range of treatment options. The market is also supported by the growing investment in research and development activities to discover new drugs and therapies for scleroderma. However, the high cost of treatment and the limited availability of effective therapies in some regions may hinder market growth.

Scleroderma Therapeutics Application and Uses

Scleroderma is a rare autoimmune disease that affects the skin and other organs of the body. There is no cure for scleroderma, but treatment can help manage its symptoms and complications. Some of the commonly used therapies for scleroderma include:
  • Immunosuppressive drugs: Drugs that suppress the immune system can help to reduce inflammation and slow down the progression of scleroderma. Some examples include methotrexate, mycophenolate mofetil, and cyclophosphamide.
  • Anti-inflammatory drugs: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and aspirin can help to reduce pain and inflammation.
  • Blood pressure medications: Drugs that dilate blood vessels can help to improve blood flow to the affected areas of the body. Some examples include calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors.
  • Skin moisturizers: Moisturizers and creams can help to soften and hydrate the skin, reducing the severity of skin symptoms.
  • Physical therapy: Exercises and stretching can help to maintain flexibility and range of motion in the affected joints and muscles.
  • Occupational therapy: Occupational therapy can help individuals with scleroderma to manage daily activities and maintain their independence.
  • Pulmonary rehabilitation: Pulmonary rehabilitation can help individuals with scleroderma to manage lung-related symptoms and improve their breathing.
  • Surgery: In severe cases, surgery may be required to treat complications such as digital ulcers or lung disease.
  • Stem cell transplant: Stem cell transplant is an experimental therapy that involves replacing the patient's bone marrow with healthy stem cells to rebuild the immune system.
The choice of treatment depends on the severity of the disease and the specific symptoms experienced by the individual. In some cases, a combination of therapies may be required to manage the symptoms and slow down the progression of scleroderma.

Global Scleroderma Therapeutics Market Segmentations


Market Breakup by Drug Class
  • Immunosuppressors
  • Phosphodiesterase 5 Inhibitors - PHA
  • Endothelin Receptor Antagonists
  • Prostacyclin Analogues
  • Calcium Channel Blockers
  • Analgesics
  • Others
Market Breakup by Indication
  • Systemic
  • Localized
Market Breakup by Treatment Type
  • Drug Treatment
  • Surgical Treatment
  • Therapy
Market Breakup by End User
  • Hospitals and Clinics
  • Homecare Settings
  • Others
Market Breakup by Region

North America
  • United States of America
  • Canada
Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
Middle East and Africa Scleroderma Therapeutics Market
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Global Scleroderma Therapeutics Market Scenario


The market is expected to grow significantly in the coming years. Scleroderma is a rare autoimmune disorder, and there are very few treatments available for it. However, as research continues to improve our understanding of the condition, there is growing hope for more effective therapies in the future.

Factors driving the growth of the scleroderma therapeutics market include an increasing prevalence of the condition, rising investment in research and development, and increasing awareness about the disease among patients and healthcare providers. In addition, the development of new and innovative treatment options is expected to drive the market growth in the forecast period.

By geography, North America is expected to hold the largest share of the market due to the high prevalence of scleroderma in the region, while the Asia-Pacific region is expected to witness the highest growth due to increasing awareness about the disease and improving healthcare infrastructure.

However, the market is also expected to face challenges such as the high cost of treatment, limited patient pool, and strict regulatory requirements. Despite these challenges, the overall outlook for the scleroderma therapeutics market is positive, with a high potential for growth and innovation in the coming years.

Key Players in the Global Scleroderma Therapeutics Market

The report gives an in-depth analysis of the key players involved in the global scleroderma therapeutics market. The companies included in the market are as follows:
  • F. Hoffman-La Roche Ltd.
  • Boehringer Ingelheim International GmbH
  • arGentis™ Pharmaceuticals, LLS
  • Kadmon Holdings, Inc.
  • Emerald Health Pharmaceuticals Inc.
  • EuBiologics Co., Ltd.
  • Astellas Pharma Inc.
  • Sanofi
  • Allergan
  • Novartis AG
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Scleroderma Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Scleroderma Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Scleroderma Epidemiology (2016-2031)
5.3 Europe Scleroderma Epidemiology (2016-2031)
5.4 Asia-Pacific Scleroderma Epidemiology (2016-2031)
5.5 Latin America Scleroderma Epidemiology (2016-2031)
5.6 Middle East & Africa Scleroderma Epidemiology (2016-2031)
6 Global Scleroderma Therapeutics Market Overview
6.1 Global Scleroderma Therapeutics Market Historical Value (2016-2022)
6.2 Global Scleroderma Therapeutics Market Forecast Value (2023-2031)
7 Global Scleroderma Therapeutics Market Landscape
7.1 Scleroderma Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Scleroderma Therapeutics: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Indication
7.2.3 Analysis by Treatment Type
7.2.4 Analysis by End User
8 Scleroderma Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Scleroderma Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Scleroderma Therapeutics Market Segmentation
11.1 Global Scleroderma Therapeutics Market by Drug Class
11.1.1 Market Overview
11.1.2 Immunosuppressors
11.1.3 Phosphodiesterase 5 Inhibitors - PHA
11.1.4 Endothelin Receptor Antagonists
11.1.5 Prostacyclin Analogues
11.1.6 Calcium Channel Blockers
11.1.7 Analgesics
11.1.8 Others
11.2 Global Scleroderma Therapeutics Market by Indication
11.2.1 Market Overview
11.2.2 Systemic
11.2.3 Localized
11.3 Global Scleroderma Therapeutics Market by Treatment Type
11.3.1 Market Overview
11.3.2 Drug Treatment
11.3.3 Surgical Treatment
11.3.4 Therapy
11.4 Global Scleroderma Therapeutics Market by End User
11.4.1 Market Overview
11.4.2 Hospitals & Clinics
11.4.3 Homecare Settings
11.4.4 Others
11.5 Global Scleroderma Therapeutics Market by Region
11.5.1 Market Overview
11.5.2 North America
11.5.3 Europe
11.5.4 Asia Pacific
11.5.5 Latin America
11.5.6 Middle East and Africa
12 North America Scleroderma Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Scleroderma Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Scleroderma Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Scleroderma Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Scleroderma Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 F. Hoffman-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Boehringer Ingelheim International GmbH
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 arGentis™ Pharmaceuticals, LLS
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Kadmon Holdings, Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Emerald Health Pharmaceuticals Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 EuBiologics Co., Ltd.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Astellas Pharma Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Sanofi
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Allergan
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Novartis AG
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Bristol-Myers Squibb Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 GlaxoSmithKline plc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
24 Scleroderma Therapeutics - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings